Lupin Ltd has reported a stellar financial performance for the fourth quarter (Q4) of FY25, with net profit surging 115% year-on-year (YoY) to ₹772 crore. The pharmaceutical giant has exceeded analysts’ expectations, driven by strong sales growth in North America and India.
Financial Highlights
- Net Profit: ₹772 crore, up 115% YoY (Estimate: ₹735 crore).
- Revenue: ₹5,667 crore, reflecting a 14.2% growth (Estimate: ₹5,564 crore).
- EBITDA: ₹1,321 crore, marking a 32.5% increase (Estimate: ₹1,244 crore).
- Margins: Expanded to 23.3%, surpassing the estimated 22.4%.
Market Performance & Growth Drivers
Lupin’s North American sales surged to ₹2,261.8 crore, up 19% YoY, fueled by new drug launches and strong demand for generics. The Indian market also grew by 7%, contributing ₹1,711.3 crore to the topline.
Dividend Declaration & Future Outlook
Following the robust earnings, Lupin’s board has recommended a ₹12 dividend per share, reinforcing its commitment to shareholder returns. Analysts remain bullish on Lupin’s growth trajectory, citing expansion in the U.S. market and a strong product pipeline.
For more updates on Lupin and pharmaceutical sector trends, stay tuned!
